leukaemia
Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients
September 2, 2016Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia
Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …
Jazz Pharmaceuticals to acquire Celator in $1.5 billion deal
May 31, 2016Manufacturing and Production, Sales and Marketing $1.5 billion, Vyxeos, acquisition, celator, jazz, leukaemia, merger, oncology
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that it has entered into a definitive merger agreement with Celator Pharmaceuticals (NASDAQ: CPXX) …
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
Second child cleared of leukaemia after Cellectis T-cell treatment
May 10, 2016Manufacturing and Production, Research and Development cellecits, childhood, children, designer cells, leukaemia, rare, t cells, t-cells
A targeted T-cell oncology therapy has successfully treated a second baby with aggressive leukaemia who has remained in remission after …
FDA grants priority review for Amgen leukaemia drug
May 4, 2016Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric
Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …
MSD teams up with Harvard to develop new leukaemia treatments
March 24, 2016Medical Communications, Research and Development AML, Harvard, MSD, leukaemia
MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
Celgene’s Vidaza earns wider approval
November 2, 2015Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia
Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …
NICE approves first in new class of leukaemia drugs
September 24, 2015Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig
NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …
NHS restriction of CML treatment in England criticised
August 27, 2015Medical Communications, Sales and Marketing NHS, NICE, chronic myeloid leukaemia, leukaemia
Medical experts have criticised NHS cost regulators’ decision to limit the use of Ariad’s Iclusig (ponatinib) in the treatment of …
Abbvie and Roche report success in Phase II leukaemia trial
August 13, 2015Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax
AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Trial results back NICE decision on Novartis cancer drug
April 15, 2015Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab
Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …
Speedy FDA nod for Amgen leukaemia drug
December 5, 2014Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia
The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …
NICE U-turn on Roche leukaemia drug
December 2, 2014Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab
NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …
NICE backs GSK’s leukaemia drug Arzerra following price cut
November 4, 2014Sales and Marketing Arzerra, CLL, GSK, NHS, NICE, leukaemia
NICE has recommended that GlaxoSmithKline’s Arzerra be prescribed under the NHS for patients with chronic lymphocytic leukaemia (CLL), after a …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
